|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi TY, Chen XJ, Zhu ML, Wang MY, He J, Yu
KD, Shao ZM, Sun MH, Zhou XY, Cheng X, et al: A pri-miR-218
variant and risk of cervical carcinoma in Chinese women. BMC
Cancer. 13:192013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng W, Liu Z, Zhang W and Hu X: miR-31
functions as an oncogene in cervical cancer. Arch Gynecol Obstet.
292:1083–1089. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bosch FX and de Sanjosé S: Chapter 1:
Human papillomavirus and cervical cancer - burden and assessment of
causality. J Natl Cancer Inst Monogr. 2003:3–13. 2003. View Article : Google Scholar
|
|
7
|
Yu Y, Zhang Y and Zhang S: MicroRNA-92
regulates cervical tumorigenesis and its expression is upregulated
by human papillomavirus-16 E6 in cervical cancer cells. Oncol Lett.
6:468–474. 2013.PubMed/NCBI
|
|
8
|
Yee GP, de Souza P and Khachigian LM:
Current and potential treatments for cervical cancer. Curr Cancer
Drug Targets. 13:205–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang F, Liu M, Li X and Tang H: MiR-214
reduces cell survival and enhances cisplatin-induced cytotoxicity
via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett.
587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Du J, Wang L, Li C, Yang H, Li Y, Hu H, Li
H and Zhang Z: MicroRNA-221 targets PTEN to reduce the sensitivity
of cervical cancer cells to gefitinib through the PI3K/Akt
signaling pathway. Tumour Biol. 37:3939–3947. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
96:(Suppl). R40–R44. 2007.PubMed/NCBI
|
|
15
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu J, Zheng Z, Wang J, Sun J, Wang P,
Cheng X, Fu L, Zhang L, Wang Z and Li Z: Different miRNA expression
profiles between human breast cancer tumors and serum. Front Genet.
5:1492014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou J, Li W, Guo J, Li G, Chen F and Zhou
J: Downregulation of miR-329 promotes cell invasion by regulating
BRD4 and predicts poor prognosis in hepatocellular carcinoma.
Tumour Biol. 37:3561–3569. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang W, Liu J, Xu T and Yu X: MiR-329
suppresses osteosarcoma development by downregulating Rab10. FEBS
Lett. 590:2973–2981. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiao B, Tan L, He B, Liu Z and Xu R:
MiRNA-329 targeting E2F1 inhibits cell proliferation in glioma
cells. J Transl Med. 11:1722013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsai MM, Wang CS, Tsai CY, Huang HW, Chi
HC, Lin YH, Lu PH and Lin KH: Potential diagnostic, prognostic and
therapeutic targets of microRNAs in human gastric cancer. Int J Mol
Sci. 17:pii: E945. 2016. View Article : Google Scholar
|
|
24
|
Yang H, Li Q, Zhao W, Yuan D, Zhao H and
Zhou Y: miR-329 suppresses the growth and motility of neuroblastoma
by targeting KDM1A. FEBS Lett. 588:192–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J
and Feng F: By downregulating TIAM1 expression, microRNA-329
suppresses gastric cancer invasion and growth. Oncotarget.
6:17559–17569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang H, Kim C, Lee H, Rho JG, Seo JW, Nam
JW, Song WK, Nam SW, Kim W and Lee EK: Downregulation of
microRNA-362-3p and microRNA-329 promotes tumor progression in
human breast cancer. Cell Death Differ. 23:484–495. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X, Lu X, Zhang T, Wen C, Shi M, Tang
X, Chen H, Peng C, Li H, Fang Y, et al: mir-329 restricts tumor
growth by targeting grb2 in pancreatic cancer. Oncotarget.
7:21441–21453. 2016.PubMed/NCBI
|
|
28
|
Sun CC, Li SJ, Zhang F, Pan JY, Wang L,
Yang CL, Xi YY and Li J: Hsa-miR-329 exerts tumor suppressor
function through down-regulation of MET in non-small cell
lung cancer. Oncotarget. 7:21510–21526. 2016.PubMed/NCBI
|
|
29
|
Wang P, Luo Y, Duan H, Xing S, Zhang J, Lu
D, Feng J, Yang D, Song L and Yan X: MicroRNA 329 suppresses
angiogenesis by targeting CD146. Mol Cell Biol. 33:3689–3699. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang HQ, Wang RJ, Diao CF, Li JW, Su JL
and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381,
and miR-655 inhibit pituitary tumor cell tumorigenesis and are
involved in a p53/PTTG1 regulation feedback loop. Oncotarget.
6:29413–29427. 2015.PubMed/NCBI
|
|
31
|
Seger R and Krebs EG: The MAPK signaling
cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
|
|
32
|
Yiwei T, Hua H, Hui G, Mao M and Xiang L:
HOTAIR interacting with MAPK1 regulates ovarian cancer skov3 cell
proliferation, migration, and invasion. Med Sci Monit.
21:1856–1863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang K, Chen H, Zhang B, Sun J, Lu J,
Chen K and Yang H: Overexpression of Raf-1 and ERK1/2 in sacral
chordoma and association with tumor recurrence. Int J Clin Exp
Pathol. 8:608–614. 2015.PubMed/NCBI
|
|
34
|
You B, Yang YL, Xu Z, Dai Y, Liu S, Mao
JH, Tetsu O, Li H, Jablons DM and You L: Inhibition of ERK1/2
down-regulates the Hippo/YAP signaling pathway in human NSCLC
cells. Oncotarget. 6:4357–4368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsubaki M, Takeda T, Ogawa N, Sakamoto K,
Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T, et al:
Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB
plays a central role in vincristine resistance in multiple myeloma
cells. Leuk Res. 39:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fei B and Wu H: MiR-378 inhibits
progression of human gastric cancer MGC-803 cells by targeting
MAPK1 in vitro. Oncol Res. 20:557–564. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li XW, Tuergan M and Abulizi G: Expression
of MAPK1 in cervical cancer and effect of MAPK1 gene
silencing on epithelial-mesenchymal transition, invasion and
metastasis. Asian Pac J Trop Med. 8:937–943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang C, Liu LY, Li ZF, Wang P, Ni L, Song
LP, Xu DH and Song TS: Effects of small interfering RNAs targeting
MAPK1 on gene expression profile in HeLa cells as revealed by
microarray analysis. Cell Biol Int. 32:1081–1090. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lwin WW, Park K, Wauson M, Gao Q, Finn PW,
Perkins D and Khanna A: Systems biology approach to transplant
tolerance: Proof of concept experiments using RNA interference
(RNAi) to knock down hub genes in Jurkat and HeLa cells in vitro. J
Surg Res. 176:e41–e46. 2012. View Article : Google Scholar : PubMed/NCBI
|
